Pfizer extends King tender offer until January
NEW YORK (Reuters) - Pfizer Inc (PFE.N) is extending its offer to buy King Pharmaceuticals Inc KG.N to January 21, the world's largest drugmaker said on Wednesday.
About 47 percent of outstanding King shares were tendered as of December 14, Pfizer said.
Pfizer agreed in October to buy King for $3.6 billion to shore up earnings ahead of the evaporation of revenue from Lipitor, its biggest product.
Pfizer, which is digesting last year's $67 billion acquisition of Wyeth, said it would use cash to pay $14.25 a share for King -- a 40 percent premium over King's closing share price before the deal was announced.
The deal would expand Pfizer's presence in the market for pain drugs by adding King's pain portfolio to products such as Lyrica and Celebrex.
(Reporting by Ransdell Pierson. Editing by Robert MacMillan)
DETROIT/NEW YORK - Ford Motor Co's board of directors plans to press Chief Executive Alan Mulally soon for a decision on his future, as speculation intensifies that he may be offered the job of CEO at Microsoft Corp.
WASHINGTON - U.S. small business sentiment bounced back from a seven-month low in November, with owners setting their sights on creating more jobs and expanding operations.
BEIJING/HONG KONG - China reiterated its opposition on Thursday to a European Union plan to limit airline carbon dioxide emissions and called for talks to resolve the issue a day after its major airlines refused to pay any carbon costs under the new law.